Xeris Biopharma: Q3 Earnings Snapshot – WTOP News
Record Recorlev demand lifted revenue 44% and pushed adjusted earnings higher, prompting Xeris to raise its full-year outlook and 2030 target.
7 Articles
7 Articles
Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
Xeris Biopharma (NASDAQ:XERS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%.
Xeris Biopharma: Q3 Earnings Snapshot – WTOP News
CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported third-quarter profit of $11.3 million. On a per-share basis, the Chicago-based company said it had profit of 6 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 2...
Xeris Biopharma Stock Soars to Multiyear High as Recorlev Sales Nearly Double and 2030 Target Tops $1 Billion
Xeris Biopharma shares surged nearly 29% after quarterly revenue rose 44%, Recorlev sales nearly doubled, profitability improved and the company raised its financial targets.
Innospec (NASDAQ:IOSP) Announces Earnings Results, Beats Expectations By $0.03 EPS
Innospec (NASDAQ:IOSP – Get Free Report) released its quarterly earnings results on Tuesday. The specialty chemicals company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.03, FiscalAI reports. Innospec had a return on equity of 9.42% and a net margin of 7.49%. The business had revenue of $473.60 million for […]
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
